Inhibikase Therapeutics, Inc.·4

Jan 7, 4:18 PM ET

McIntyre David 4

4 · Inhibikase Therapeutics, Inc. · Filed Jan 7, 2026

Insider Transaction Report

Form 4
Period: 2026-01-05
McIntyre David
Chief Financial Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2026-01-05+986,319986,319 total
    Exercise: $2.01Exp: 2036-01-05Common Stock (986,319 underlying)
Footnotes (1)
  • [F1]The shares underlying the option shall vest and become exercisable in 36 equal monthly installments commencing from January 5, 2026, subject to the Reporting Person's continued employment through each such vesting date.

Documents

1 file
  • 4
    ownership.xmlPrimary

    4